Last reviewed · How we verify

Intralesional 5-fluorouracil

Maharajgunj Medical Campus · Phase 2 active Small molecule

Inhibits thymidylate synthase

Inhibits thymidylate synthase Used for Actinic keratosis, Basal cell carcinoma.

At a glance

Generic nameIntralesional 5-fluorouracil
SponsorMaharajgunj Medical Campus
Drug classPyrimidine analog
TargetThymidylate synthase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

5-fluorouracil works by inhibiting thymidylate synthase, an enzyme involved in DNA synthesis, thereby preventing cancer cell growth.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: